Image-Guided Therapy for Cancer
- 詳細技術說明
- Prof.Schultz’s lab at the University of Iowa has developed a novel image guided therapyfor cancer. This invention relates to aclass of molecules, tetra-arylethylene derivatives, that can specificallydeliver drugs to mitochondria in tumor cells. Data demonstrates that this platform can bedesigned to accumulate in the melanoma mitochondrial membranes, disrupt tumorcell metabolism, and induce cell death. Inaddition, this invention allows for imaging the accumulation of the deliveryvehicle molecule in cells, a novel property of lipophilic cations.
- *Abstract
-
The globalmelanoma therapeutics market is expected to rise to $12.4 billion by 2025, dueto the alarming increase of worldwide cases. Melanoma is a type of skin cancerthat is caused by UV radiation and genetics. It is the sixth most diagnosed cancer in theUnited States. Unlike other cancers, theprevalence of melanoma is increasing, with the highest occurrences amongindividuals 25-29 years old. The overalllifetime risk of developing melanoma is 2.4%, and if treated early, there is a97% survival rate. Currently, there are5 types of treatments available; surgery, immunotherapy, chemotherapy,radiation therapy, and targeted therapy. A largeissue is that melanoma can migrate to other parts of the body, and the one yearsurvival rate drastically decreases.
Prof.Schultz’s lab at the University of Iowa has developed a novel image guided therapyfor cancer. This invention relates to aclass of molecules, tetra-arylethylene derivatives, that can specificallydeliver drugs to mitochondria in tumor cells. Data demonstrates that this platform can bedesigned to accumulate in the melanoma mitochondrial membranes, disrupt tumorcell metabolism, and induce cell death. Inaddition, this invention allows for imaging the accumulation of the deliveryvehicle molecule in cells, a novel property of lipophilic cations.
Advantages
· Targetsand kills cancer cells, specifically melanoma
· Allowsfor precise visualization of therapeutic in cancer cell
· Bettermonitorization of effects compared to current technology
· Conjugationto artemisinin, which is an antimalarial that has potential as a cancertreatment
Related Technologies
2011-034
2013-039
- *Licensing
- MihaelaD. Bojin, PhD, CLP LicensingAssociateUniversityof Iowa Research Foundation2660UCCIowaCity, Iowa 52242Phone:(319) 335-2723Email: mihaela-bojin@uiowa.edu
- 國家/地區
- 美國
